ESPE Abstracts

Obesity remains a critical global health concern. Traditional treatment often yields limited results, necessitating innovative solutions. The Evira tool; comprising a digitless scale and a mobile application with real-time feedback, addresses these challenges by enhancing home- based monitoring. The primary aimwas to evaluate its efficacy for childhood obesity treatment in Abu Dhabi, with a secondary objective to establish non-inferiority compared to outcomes in Stockholm, Sweden. Participants aged 6-15.9 years from Abu Dhabi, commenced treatment between June and December 2023. Regular physical visits at baseline, 3 months, and 6 months, alongside questionnaire assessments, facilitated data collection via electronic case report forms. Comparative analysis with the Stockholm cohort treated between October 2018 and February 2019, illustrated similar participant demographics and treatment protocols. Daily home-weighings, synchronized via Bluetooth to parental smartphones and clinic interfaces, facilitated dynamic visualization of BMI Z-scores. Statistical analyses, including descriptive statistics and Mann-Whitney U tests assessed primary outcomes specifically changes in BMI Z-scores from baseline to 26 weeks. Within the Abu Dhabi cohort, 48 patients (46% males) were included. At treatment initiation, mean age was 12.2 years and mean BMI Z-score was 2.93. Moreover, within the Stockholm cohort, 107 patients (67% males) generated a mean age of 11.9 years and a mean BMI Z- score of 2.76 at treatment initiation. At the final follow-up, 32 patients in the Abu Dhabi cohort and 75 patients in the Stockholm cohort were still engaged in treatment. The proportion of individuals reaching a significant change in relative weight as proportion of patients with recorded measurements, defined as a decrease of -0.20 BMI Z-score units after 6-months of treatment was 34% in the Abu Dhabi cohort and 39% in Stockholm. Results indicated that the Abu Dhabi cohort achieved a mean reduction of 0.22 BMI Z-score units after 26 weeks. This outcome paralleled findings from the Stockholm cohort, where a reduction of 0.21 was achieved - highlighting the tool's efficacy across diverse settings. Non- retention rates, a common challenge in obesity studies, were notably lower in both cohorts compared to expected norms due to weekly, consistent communication to stress compliance. In conclusion, findings from this trial support the non-inferiority of Evira in childhood obesity management in Abu Dhabi relative to Stockholm. The study also underpins the tool's potential to deliver benefits in varied healthcare environments. Future research should explore long-term impacts and adaptability of such technologies in regional healthcare practices to combat childhood obesity.